Abstract
Beneficial efficacy for type 2 diabetes (T2D) and Metabolic syndrome (Met-S) by vildagliptin/metformin (EquMet)
Full Text
Sign-in/Register to access full text options
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Endocrinology and Diabetes
Paper Title
Journal
Date